Trials / Completed
CompletedNCT05406115
Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity
A Phase 1, Randomized, Double-blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 786 in Healthy Subjects and Subjects With Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to assess the safety and tolerability of AMG 786 as single or multiple doses in healthy and obese participants.
Detailed description
The 4th Multiple Ascending Dose cohort was not started.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 786 | Oral tablet |
| OTHER | Placebo | Oral tablet |
Timeline
- Start date
- 2022-07-26
- Primary completion
- 2023-08-21
- Completion
- 2023-08-21
- First posted
- 2022-06-06
- Last updated
- 2025-10-27
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05406115. Inclusion in this directory is not an endorsement.